前苏联专利SU1750425A3 Method of obtaining aromatic and heteroaromatic compounds

专利PDF首页>>前苏联专利

专利附录

专利说明

权利要求

类似技术

同族专利

引用文献

法律状态

优先权

专利摘要:
Cognitive defeciencies or neurological dysfunction in mammals are treated with alpha , alpha -disubstituted aromatic or heteroaromatic compounds. The compounds have the formula: <CHEM> or a salt thereof wherein X and Y are taken together to form a saturated or unsaturated carbocyclic or heterocyclic first ring and the shown carbon in said ring is alpha to at least one additional aromatic ring or heteroaromatic ring fused to the first ring; one of Het<1> or Het<2> is 2, 3, or 4-pyridyl or 2, 4, or 5-pyrimidinyl and the other is selected from (a) 2, 3, or 4-pyridyl, (b) 2, 4, or 5-pyrimidinyl, (c) 2-pyrazinyl, (d) 3, or 4-pyridazinyl, (e) 3, or 4-pyrazolyl, (f) 2, or 3-tetrahydrofuranyl, and (g) 3-thienyl.
公开号:SU1750425A3
申请号:SU884356717
申请日:1988-10-05
公开日:1992-07-23
发明作者:Алан Ерл Ричард；Джон Майерз Мелвин；Йоханнес Никлсон Виктор
申请人:Е.И.Дюпон Де Немур Энд Компани (Фирма)；
IPC主号:

专利说明:

It is designed to treat mental deficiencies and / or neurological functions and / or psychological disturbances.
The invention relates to a method for producing new biologically active t, cxi -disubstituted aromatic and heteroaromatic compounds that can be used in medicine.
The purpose of the invention is a method for producing N, (- disubstituted aromatic and heteroaromatic compounds that increase the release of acetylcholine in the nervous tissue with
PRI me R 1. Bis-methanesulfonate 1,1-bis (4-pyridinylmethyl) nyl-1H-indene.
To a cooled (-20 ° C) solution of 3 phenyl-1H-indene (5.0 g, 26 mmol) in tetrahydrofuran (THF) (70 ml) was added n-butyl lithium (1.1 equivalent, 1.17 M, 28 , 6 mmol),, 5 ml (dropwise). After stirring for 30 minutes, a solution of 4-picolyl chloride (1.5 equivalents, 39 mmol, 5.0 g) in THF (70 ml) o was added. This solution was heated to 0 ° C and maintained at this temperature for 1 hour. The mixture was cooled again to -20 ° C and n-butyl lithium and 4-picolyl chloride were added as described. The solution was then heated to 0 ° C for about 2 hours. The reaction mixture was rapidly cooled by adding saturated ammonium chloride solution and diluted with ether. The organic phase was washed with water, brine, and dried over magnesium sulfate. Removing the solvent using a rotary evaporator gave an oil that was purified on a chromatography column (silica gel, dichloromethane, methanol from 60: 1 to 20: 1) to obtain 1,1-bis (4-pyridinylmethyl) 3 phenyl-1H-indene in the form of a solid, 5.8 g 15.5 mmol, yield 60%.
NMR (200 MHz, CDC13): 3.18 (double doublet, 4H); 6.23 (singlet, 1H); 6.79 (doublet, 4H, J 6 Hz); 7.12 (multiplet, 4H); 7.29 (multiplet
4H); 7.51 (doublet, 1H, J 7 Hz); . 8.28 (doublet, 4n, J 6 Hz).
Mass Spectrum 374.
To a solution of (4-pyridinylmethyl) -3 phenyl-1H-indene (1.0 g,
2.7 mmol) in methylene chloride were added methane sulfonic acid (5.4 mmol, 0.52 g, 0.35 ml). The solvent was evaporated, and the residue was recrystallized from ethyl acetate: isopropanol to obtain white crystals, 0.8 g, m.p. 250 ° C
Example2. 4-, 3-DIhydro-3-phenyl-1 (4-pyridinyl-methyl) -1H-inden-1-ylmethyl-D) pyridine chlorohydrate.
To a solution of 1f1-bis (4-pyridinylmethyl) -3-phenyl-1H-indene (5.8 g, 15.5 mmol) in 95% ethanol
(100 ml) 5% palladium on a carbon catalyst (1.45 g) was added and the mixture was shaken in a hydrogen atmosphere (3.5 kg / cm 2) at room temperature for 2 hours. Catalyst 5 was removed by filtration, and the solvent was removed on a rotary evaporator. The oil was purified on a chromatography column (silica gel, 10% methanol / dichloromethane),
0 to obtain pure 3-dihydro-3-phenyl-1 - (4-pyridinylmethyl) inden-1-ylmethylL pyridine
NMR (200 MHz, HL) C13) Ј: 2.05 (double doublet, 1H); 2.38 (double doublet, 1H); 2.93 (double doublet, 2H); 3.15 (double doublet, 2H); 3.42 (multiplet, 1H); 6.67 (double doublet, 4H) 7.00 (doublet, 2H); 7.10 - 7.34 (multiplet, 7H); 8.36 (doublet,
0 2H, J 5 Hz); 8.42 (doublet, 2H, -J 5Hz).
Mass spectrum: 376, 1937, (calculated for, 376, 1951 (found) on
The oil was dissolved in methanol and HCl was added in ether to precipitate the salt. After recrystallization from isopropanol: ethyl acetate
-s1
a white solid was obtained, 6.2 g, mp: 210-225 ° C
Example 3 3,3-bis (4 pyridinylmethyl) -2.3 dihydro-1-phenyl-1H-inden-1,2-diol diacetate.
To a solution of 1,1-bis (A-pyridinylmethyl) 3-phenyl-1H-indene (1.0 g, 2.7 mmol) in dry pyridine (10 ml) was added metryoxide (1.0 g 3.9%). mmol} dissolved in ether. The mixture was stirred at room temperature and analyzed by TLC. After the completion of the reaction, sodium bisulfite (2.0 g), water (20 ml) and pyridine (5 ml) were added. The mixture was stirred in for 1 h and extracted three times with chloroform: isopropanol (A: 1). The combined extracts were washed with brine, dried over magnesium sulfate and evaporated, to give 3,3-bis (A-pyrid inyl-methyl) - 2,3-dihydro-1-phenyl-1H-inden-1,2-diol as a yellow solid, 1.15 g,
The crude 3, (A-pyridinylmethyl) -2,3-diHydro-1-phenyl-1H-inden-1,2-diol was again dissolved in pyridine (20 ml) and acetic anhydride (C ml) was added. The mixture was heated to 50 ° C for 2 days. After cooling, the volatile materials were removed under vacuum, and the residue was redissolved in dichloromethane and water. The aqueous layer was converted to slightly alkaline with potassium carbonate and extracted several times with dichloromethane. The combined extracts were dried over sodium sulfate, and the solvent was evaporated to obtain an oil. This material was purified on a chromatographic column (silica gel, 10% methanol: dichloromethane) to give 3, (A-pyridinyl-methyl) -2.3 dihydro-T-phenyl TH-indene-1,2-diol diacetate in the form of butter.
NMR (200 MHz, 2.06 (singlet, ZN) 2.11 (singlet, S); 3.05 - 3.9 (2 double doublets, AN); 5.28 (singlet, 1H); 6.6A (double doublet, 1H); 6.89 (multiplet, 6H); 7.26 (multiplet, et 5H); 7.60 (double doublet, 1H); 8.27 (doublet, 2H, J 6 Hz 8., 51 (doublet, 2H, J 6 G4).
Mass Spectrum: A92, (calculated for C3 (H28N2Q,); (found
To solution 3, (A-pyridinylmethyl) -2, 3-DIHYDRO-1-phenyl-1H-indene 5b
1,2-diol diacetate in dichloromethane was added an excess amount of HC 1 in dichloromethane. The solvent was removed, and the residue was recrystallized from ethanol: ethyl acetate to obtain a white solid, 0.42 g, m.p. 300 ° C.
PRI me R A. 1,1-Bis (A-pyridinyl-methyl) -3, A-dihydro-7-methoxy-2- (1H) - naphthalenone,
To a suspension of sodium hydride (60% - per oil per dispersion, 1.6 g, 0, OA mol) in 30 ml of dry 1,2-dimethoxyethane was added dropwise a solution of 7 methoxy-2-tetralone (3.6 g, 0.02 mmol) in 30 ml of dry 1,2-dimethoxy ethane. The reaction mixture turned yellow and after all the tetralon was added, the mixture was slowly heated to reflux for 15 minutes. A-picolyl chloride solution was prepared by dissolving 4-picolyl chloride hydrochloride (6.56 g, 0.0 mol) in 100 ml of water, then the solution was alkalized with sodium bicarbonate and the free base was extracted with ether (200 ml). After drying over sodium sulfate, the mixture was filtered, and the ether was removed on a rotary evaporator. The residue was immediately redissolved in 1,2-dimethoxyethane (30 ml). This solution was added dropwise to the hot reaction mixture and heated-t mixture until refluxed for 6 hours. The reaction mixture was cooled and methanol (10 ml) was added to decompose excess sodium hydride. The solvents were evaporated, and the brown oily residue was dissolved in 200 ml of dichloromethane. The organic phase was washed with water and dried over sodium sulfate. After filtration and processing on a rotary evaporator, the crude product was purified on a chromatographic column (silica gel, 10% ethanol in ethyl acetate). The product thus obtained was recrystallized from ethyl acetate to obtain 1,1-bis (-pyridinylmethyl-3, k-igidro-7 methoxy-2 (1H) -naphthalenone as a white solid, 1.5 g, mp 125 -127 S.
NMR (200 MHz, CDC13): 3.13 - 3.19 (doublet, AN); 3.6 - 3.52 (doublet, M); 3.92 (singlet, WL; 6.66 - 6.67 (doublet); 8.27 - 8.30 (dulet, H),
ten
15
IR, cm-H 1707, 1599
Mass spectrum “С 77.06; H 6.18; N 7.81; (calculated for C, 77.21; H, 6.13; N, 7.76 (found).
ExampleB 11,11-bis (L-pyridinylmethyl) LH-dibenzf hydrochloride, d cyclohepten-10 (11H) -one „
To a suspension of sodium hydride (60% - per oil per dispersion, 1.6 g, 0.04 mol) in 30 ml of dry 1,2-dimethoxy4 ethane was added dropwise a solution of 5.11-dihydro-10H-dibenzo a, cG cyclohepten-10-one (4.16 g, 0.02 mmol) in 30 ml of dry 1,2-dimethoxyethane. After all the ketone was added, the mixture was slowly heated to reflux for 1 hr. A solution of 4-picolyl chloride was prepared by dissolving 4-picolyl chloride hydrochloride (6.56 g, 0.04 mol) in 100 ml of water, basifying the solution with sodium bicarbonate and extract the free base with ether (200 ml). After drying over sodium sulfate, the mixture was filtered, and the ether was removed on a rotary evaporator. The residue was immediately redissolved in 1,2-dimethoxyethane (30 ml) o This solution was added dropwise to the hot reaction mixture and the mixture was heated to reflux for 6 hours. The reaction mixture was cooled and methanol (10 ml) was added to decompose excess sodium hydride. The solvents were evaporated, and the residue was dissolved in 200 ml of dichloromethane.
The organic phase was washed with water and dried over sodium sulfate. After filtration and processing on a rotary evaporator, the crude product was subjected to purification on a chromatographic column (1 silica gel, 10% methanol: dichloromethane). The product thus obtained was a viscous oil.
NMR (200 MHz, CDC1); 3.43-3.49 schuolet, H); 3, / b - 3, “2 (doublet, 1H); 4.16 - 4.19 (doublet, 1H); 4.42 20
25
salt in the form of an amorphous hygroscopic solid, t „pls 300 С
A compound is obtained analogously, where A is -CH2CH2-, mp 300 ° C.
PRI me R 6, 9, (4-pyridi nilmethyl) xantaNo
5.1 g (0.028 mol) of xanthan was dissolved in 50 ml of dry tetrahydro furan and cooled to -30 ° C. Then 3.11 g (0.029 mol) of lithium diisopropyl amide was weighed into a separatory funnel and dissolved in 30 ml of tetra hydrofuran. This solution was added dropwise over 30 minutes to a xant new solution at -30 ° C. After the addition was complete, the solution was heated to room temperature and kept at this temperature for 15 minutes. Then it was cooled again to -30 ° C and 5.05 g (0.01 mol) of 4-picolyl chloride in 1b ml of tetrahydrofuran was added dropwise over 30 minutes at 30 ° C. After the addition was complete, the reaction mixture was warmed to room temperature and kept at that temperature for 30 minutes. Again, the mixture was cooled to -30 ° C, another drop of 3.11 g (0.029 mol) of diisopropyl and lithium in 30 ml of tetrahydrofuran was added dropwise over 30 minutes at -30 ° C. After the addition was complete, the mixture was warmed to room temperature and kept at that temperature for 15 minutes. After cooling again to -30 ° C, another portion of 4-picolyl chloride (0.03 mol in 15 ml of tetrahydrofuran) was added dropwise over 30 minutes at -30 ° C. After additions were added, the reaction mixture was heated to room temperature and kept there until it was determined using thin-layer chromatography (45) that the reaction was over, approximately 10 hours. The excess anion was carefully destroyed by adding 50 ml of a saturated solution of ammonium chloride, and
thirty
40
4.49 (doublet, 1H); 4.86 - 4.93 (multi-TrahydrofURan was evaporated under a water-coat, 2H); 7.02 - 7.88 (multiplet, 8H); 8.52 (doublet, 2H); 8.55 (doublet,
2H) 0
IR Spectrum, 1675, 1598 This oil was dissolved in ether and treated with a solution of hydrogen chloride in ether to obtain the indicated chlorohydrate
cuum The residue was taken up in methyl chloride and the product was extracted with ml of 0.5N hydrochloric acid. Hydrochloric acid, combined with 55 hydrochloric acid, was made alkaline with 50% sodium hydroxide solution to pH 12 and the product was extracted with methylene chloride. Methylene chloride soy extracts
0
five
five
0
five
salt in the form of an amorphous hygroscopic solid, t „pls 300 C„
A compound is obtained analogously, where A is -CH2CH2-, mp 300 ° C.
PRI me R 6, 9, (4-pyridinylmethyl) xantaNo
5.1 g (0.028 mol) of xanthan was dissolved in 50 ml of dry tetrahydrofuran and cooled to -30 ° C. Then 3.11 g (0.029 mol) of lithium diisopropyl amide was weighed into a separatory funnel and dissolved in 30 ml of tetrahydrofuran. This solution was added dropwise over 30 minutes to the xanthan solution at -30 ° C. After the addition was complete, the solution was heated to room temperature and kept at that temperature for 15 minutes. Then it was cooled again to -30 ° C and 5.05 g (0.01 mol) of 4-picolyl chloride in 1b ml of tetrahydrofuran was added dropwise over 30 minutes at 30 ° C. After the addition was complete, the reaction mixture was warmed to room temperature and kept at that temperature for 30 minutes. Again the mixture was cooled to -30 ° C, another drop of 3.11 g (0.029 mol) of lithium diisopropylamide in 30 ml of tetrahydrofuran was added dropwise over 30 minutes at -30 ° C. After the addition was complete, the mixture was warmed to room temperature and kept at that temperature for 15 minutes. After cooling again to -30 ° C, another portion of 4-picolyl chloride (0.03 mol) in 15 ml of tetrahydrofuran was added dropwise over 30 minutes at -30 ° C. After the addition was complete, the reaction mixture was heated to room temperature and kept it until it was established using thin-layer chromatography 5 that the reaction was over, about 10 hours. The excess anion was carefully destroyed by adding 50 ml of a saturated solution of ammonium chloride, and
0
0
teTragidrofURan evaporated under cottonTragidrofURan evaporated under vacuum. The residue was taken up in methylene chloride and the product was extracted with ml of 0.5N hydrochloric acid. The combined portions of hydrochloric acid were made alkaline with a 50% sodium hydroxide solution to pH 12 and the product was extracted with methylene chloride. The methylene chloride extracts were combined, washed with water, dried with magnesium sulfate, filtered, and evaporated. The crude product was triturated with ether to obtain 2.0 g of product. This material was subjected to silica chromatography using a mixture of hexane: ethyl acetate (70:30). The fractions containing the product were combined and evaporated to give 1.7 g of the disubstituted product. He was subjected to recrystallization from chlorobutane to obtain 1.1 g of dialkylated xanthan, t g) l 212 - 213 ° С „,
PRI me R 7. 9.9 Bis (-pyridi nilmethyl) fluorene
3.0 g (1 &, 0 mmol) of fluorene was dissolved in 20 ml of tetrahydrofuran and cooled to -20 ° C under nitrogen atmosphere. N-Butyl lithium (11.5 ml, 1.5 / M ). After stirring for 30 minutes, it was transferred to a solution of 18.0 mmol of A-picolyl chloride in 20 ml of THF at -78 ° C. After the mixture was allowed to warm to room temperature, TLC (ether: hexane 1: 1) confirmed that there was no fluorene. The mixture was again cooled to -20 ° I. A second portion of 11.5 ml of n-butyl lithium (1.57 M) was added dropwise over 15 minutes. After stirring for 30 minutes, the reaction mixture was transferred to a solution of 18.0 mmol of 4-picolyl chloride in 20 ml of THF at -78 ° C. The resulting mixture was heated to room temperature and then stirred at ambient temperature. temperature for 17 hours. The reaction was quickly stopped with a saturated solution of ammonium chloride and extracted with ether. The crude combined extracts were chromatographed with a mixture of methylene chloride: methanol (30: 1) and (25: 1) to obtain 2.9 g of the number of the indicated dialkylated fluorene.
Mass spectrum:, 1613 (m), 256, 1131 (M-C6H6N).
PRI me R 8. 9, (4-pyridinylmethyl) thioxanthen „
9 (4-pyridinylmethyl) thioxanthen.
4.96 g (0.025 mol) of thioxantane was dissolved in 25 ml of THF and cooled to -20 ° C. Under stirring, 18 ml was added dropwise over 30 minutes.
s
0 5 0 5 0 5
0
five
1, A M solution of hexamethyldisilazide potassium. After the addition was complete, the reaction mixture was heated to room temperature and kept at that temperature for 15 minutes. Then it was cooled to -20 ° C and 4-picolyl chloride (28.0 mmol), base, in 20 ml of THF was added dropwise over 30 minutes at -20 ° C. After the addition, the reaction mixture was heated to room temperature and kept for 1 hour. The reaction was quickly stopped by the addition of 50 ml of a saturated solution of ammonium chloride and evaporated. The residue was extracted with methylene chloride, subjected to successive acidic and alkaline washing with 0.5 n hydrochloric acid solution and 50% sodium hydroxide. The organic layer was dried (magnesium sulfate) and evaporated to give 5.1 g of the indicated monoalkylated product.
9, (4-pyridinylmethyl) thioxane
Slowly added 0.38 g (8.0
mmol) 50% oil dispersion of sodium hydride for 15 minutes in 20 ml of dimethyl sulfoxide at room temperature. After the addition was complete, the reaction mixture was heated to 5 ° C over 30 minutes. It was cooled to 15 ° C and a solution of 2.3 g (8.0 mol) 9 (α-pyridinyl-methyl) thioxanthene in 10 ml of dimethyl sulfoxide was added dropwise to for 15 min at room temperature. After the addition was complete, the reaction mixture was stirred for 30 minutes at room temperature. Then a solution of 4-picolyl chloride (8, / 5 mmol) in 5 ml of dimethyl sulfoxide was added dropwise over 30 minutes at ambient temperature. The mixture was then heated to 40 ° C for 30 minutes. The reaction was quickly stopped by adding water (50 ml). The result of grinding the precipitated oil was a crystalline solid, which was isolated by filtration, washed with water and dried. The tan solid was dissolved in benzene and decolorized with stirring with 1 g of Magnesol for 30 minutes. After evaporation and filtration, a yield of
colorless product (2.0 g), which was subjected to recrystallization from ethyl acetate, so l. 201.4 - 203, S.
Example 9. In analogy to Example B, the following compounds were prepared.
Chloride dihydrate, y, 9-bis (4 pyridinyl-methyl) -1-methylfluorene (a), tspl, 300 ° C.
NMR (200 MHz,) ff: 2.82 (singles, 3N); 3.60 (double doublet, 4H); 6.39 (multiplet, 4n); 7.0 - 7.5 (multiplet, 7H-flavor.); 8.0 (multiplet, 4H) o
High dilution mass spectrum: 362, 1783; calculated for); 362, 1779 (found)
Chloride dihydrate 959-bis (4 pyridinyl-methyl) -2-bromofluorene (c), melting point 300 ° C.
NMR (200 MHz, CDC13): 3.39 (double doublet, 4H); 6.48 (doublet, 4H); 7.10 - 7.67 (multiplet, 7H-flavor.) 8.12 (doublet, J 5.7 Hz, C) „
HRMS mass spectrum: 426.0758 (ra
read, for C25HigBrN2), 426, 0758 (found).
9, (4-pyridinylmethyl) -2-methylfluorene (c):
NMR (CDClg, 200 MHz): 2.4 (singlet, 3N); 3.37 (singlet, 4H); 6.49 (doublet, J = 5.3 Hz, 4H); 7.03 - 7.45 (aroma. H); 8.09 (doublet, 4H) „
Mass Spectrum: 362, 1783 (calculated for C, 6H22N2) j 362, 1778 (found) o
9,9-Bis (4-pyridinylmethyl) -2-ethyl-fluorene (d) o
NMR (CDC13, 200 MHz) Y: 1.30 (triplet, J 7.8 Hz, 3N); 2.74, (quattet, J = 7.6 Hz, 2H); 3.37 (4H singlet); 6.49 (doublet, J = 5.9 Hz, 4n); 7.04 - 7.48 (multiplet, aroma 7H) 8.09 (doublet, J 5, i Hz, M).
Mass spectrum: 376, (calculated for Cg Hg4H2); 376, 1927 (found).
Chlorohydrite 9,9-bis (4-pyridinyl-methyl) -2-methoxyfluorene (e) with
NMR, &: 3.37 (singlet, 4H); 3.89 (singlet, ZN); 6.52 (broad, N); 6.80 (multiplet, 1H); 7.01 (doublet
J 2.1 Hz, 1H); 7.26 (multiplet, 5H); 7.5 (doublet, J 7.5 Hz, 1H); 8.11 (wide, 4n).
I
9, (3 pyridinylmethyl) fluorene
(1) m.p. 137 - 138 ° С
five
0
five
0
five
0
five
50
55
NMR, 8: 3.1 (singlet, F); 6.71 - 6.97 (multiplet, kH); /, 1 / - 7.33 (triple triplet, 6n); 7.50 - 7.5 (doublet, J 6.9 Hz, 2H); 7.91 (singlet, 2H); 8.12 - 8.15 (doublet, I 5.4 Hz, 2H).
Mass Spectrum:, 1632 (calculated for C H N N); , 1b2b (found) about
Example 10. 5, (4-pyridinylmethyl) 5H-cyclopentar, 1-b: 3.41 J- dipyridine.
The compound was prepared, following the procedure of Example 1, from 0.43 g (2.56 mmol) of 4,5-diazafluorene, 0.84 g of 4-picolyl chloride hydrochloride, 29.0 mg of benzyltriethyl ammonium, 3 ml of 50% a-sodium hydroxide and 30 ml of toluene by reacting at 50 ° C for 6 hours. The crude product was subjected to chromatography (ethyl acetate: methanol 99: 1) and recrystallized from isopropyl alcohol
NMR (CDC13, 200 MHz): 3.42 (singlet, 4H); 6.52 (doublet, J 5.7 Hz,
4H); 7.33 (double doublet, 2H); 7.85 (doublet, 2H); 8.16 (doublet, J = 5.6 Hz, 4H); 8.61 (doublet, 2H) „
PRI me R 11. 9,9-Bis (4-pyridinylmethyl) indeno 2,1-b pyridine.
47.5 g (0.25 mol) of 4-azafenanotene were dissolved in 750 ml of glacial acetic acid. 110 g (0.33 mol) of iodine pentoxide were added with vigorous stirring. The mixture was heated under gentle reflux and kept in this state for 6 hours. Then the reaction mixture was cooled to room temperature, and the excess iodine pentoxide was separated by filtration. The solution was treated on a rotary evaporator, and the residue was transferred to benzene. This solution was washed with sodium thiosulfate to remove excess iodine. It was then dried with sodium sulfate, filtered and evaporated to give 20 g of 4-phenanthrene-5, 6-dione. After recrystallization from ethanol, 13.0 g of pure dione was obtained, TRPL. 262 C,
The transformation of 4-azafenanthrene 5,6-dione in 1-azafluoren-9 he
A solution of 4-azaphenanthrene-5,6-dione (10.76 g / 51 mmol) was added to 200 ml of a 10% sodium hydroxide solution in an Erlenmeyer flask.
The flask was placed in a bath and heated to 70-80 ° C for 2 hours. When TLC was shown to be complete, the mixture was cooled to room temperature and extracted with chloroform. It was dried with sodium sulfate and evaporated to give a tan product. After flash chromatography with ethyl acetate, 4.79 g of pure 1-azafluoren-9-one were obtained, m.p. 129 - 130 ° C
Recovery of 1-azafluoren-9-she in 1-azafluoren,
4.6 g (25.4 mmol) of 1-azafluoren-9-one were added to a solution of 9 ml (0.28 mol) of hydrazine and 50 ml of diethylene glycol. Heating was started and the temperature was maintained at 100 C for 15 minutes, then lifted to 195 ° C and kept at this temperature for 1 hour. It was determined by TLC that the reaction was complete. The reaction solution was cooled to a temperature below 100 ° C and poured into 300 ml of ice water. The aqueous phase was saturated with salt and extracted with ml of ether. The ether was dried with sodium sulfate and evaporated to give g of crude product. It was dissolved in hexane and treated with Magnesol, filtered, evaporated and recrystallized from hexane to obtain 2.83 g of pure 1-azafluorene,
Preparation 9, (4-pyridinyl-methyl) indeno 2,1-b pyridine.
2.0 g (42 mmol) of a 50% sodium hydride solution were suspended in a 4-necked flask (250 ml) with a round bottom, equipped with an inlet for nitrogen, a cooler, a thermometer, an additional funnel, a magnetic stirrer and 25 ml of sodium-dried THF and 2.5 g (15 mmol) of 1-azafluoren. The mixture was allowed to stir at room temperature for 1 hour. 6.6 g (mmol) of 4-picolyl chloride hydrochloride was dissolved in a minimal amount of water and cooled to 0-5 C. Carefully maintaining the temperature below 5 ° L, it was alkalized with ammonium hydroxide , quickly extracted with benzene, dried with potassium carbonate and filtered. A benzene solution of 4-picolyl chloride was added to the reaction mixture over 15 minutes. After
0
five
0
five
0
five
0
five
The completion of the addition was heated to 60 ° C until it was determined by TLC that the reaction was complete (FtOAc-CHoOH; 90:10), R. 0.13. The reaction mixture was cooled and decomposed with a saturated solution of ammonium chloride. The layers were separated and the organic phase was extracted with benzene. It was dried with potassium carbonate and evaporated to obtain 6.0 g of crude product. By flash chromatography (ethyl acetate), 4.0 g of product was obtained, which was recrystallized from butyl chloride to obtain 2.49 g, mp. 204.7 - 20b, 0 ° С
Mass spectrum: calculated mass 349, 1528; the difference is 0.0004; C2,
NMR (20U MHz, CDCL) i: 3.394-3.718 (double doublet, 4H, -CH2-pyridyl); 6.437 (doublet, 4n, p-pyridyls); 7, Yu7 - 7.635 (multiplet, 6H, flavor.); 8.027 - 8.057 (doublet, 4H, L pyridyls); 8.589 - 8.621 (double doublet, 1H, with -CHM-azafluoren) „
Example 12. 5,5-Bis (4-pyridinylmethyl) indeno 1,2-tpyridine0
Preparation of 1-azafenanthrene-5,6-dione.
Following the procedure described in Example 11, 37.5 g (0.153 mol) of 1-azafenanthrene and 55 g (0.165 mol) of iodine pentoxide in 600 ml of glacial acetic acid were refluxed for 2 hours. Identical treatment yielded 8.4 g, tons. square 215 - 216 ° C.
Conversion of 1-azafenanthrene-5,6-dione to 4-anafluoren-9 it.
Following the procedure described in Example 11, 8.2 g (0.04 mol) of 1-azafenanthrene-5, 6-dione and 165 ml of a 10 d solution of sodium hydroxide solution were heated in a bath at 80 - 90 ° C for 3 hours. as a result of identical treatment, 3.88 g of pure 4-azafluoren-9-one, 140 - 142 i.
Recovery of 4-azafluoren-9 is 4-azafluoren.
50
Following the procedure described in Example 11, 3.45 g (19 mmol) of 4-azafluoren-9-one, 6.8 g (0.213 mol) of hydrazine in 50 ml of diethylene glycol were combined and heated to 205 C for 30 minutes. TLC showed no starting material. An identical treatment of 2.33 g of pure was obtained.
15
4-azafluorene, Rj 0.46 (hexane: ethyl acetate: triethylamine 29.75: 69.46: 0.79).
Preparation of 5, (4-liridinylmethyl) indeno 1, 2-b pyridine0
Following the procedure described in Example 11, the alkylation of 2.1 g (12.6 mmol) of 4-azafluorene in the presence of 1.51 g (31.45 mmol) of 50% sodium hydride with 5.0 g (30.4 mmol ) 4-picolyl chloride gave 2.8 g. After flash chromatography using ethyl acetate, 2.0 g of material containing a small amount of a coloring substance was obtained. After recrystallization from butyl chloride, 1.5 g of pure compound were obtained, mp. 163 - 164 ° C.
Mass spectrum: 349.1579 (calculated for) 349.1570 (found).
NMR (200 MHz, CDC13): 3.407 (singlet, 4H, -CH-pyridyl); 6.4-8 - 6.529 (double doublet, 4H, P-pyridyls); 7.149 7.770 (multiplet, 6H, flavor.); 8.1) 7 - 8.167 (doublet, 4 °, Oi-pyridyls); 8,437. - 8.469 (double doublet, 1H, (Xf-CHN-sugated).
Example 13. 9,9-Bis (4-pyridinylmethyl) cyclopenta Ј1, 2-b: 3,4-blJ dipyridine)
Getting 1.5 Diazafluoren-9-she.
11.8 g (0.178 mol) of potassium hydroxide was dissolved in 2000 ml of water in a 5-liter multi-neck flask with a round bottom. To this solution, 18.0 g (0.1 mol), 1,7-Diazaphenant-rolin was added. The mixture was heated to boiling, and the 1.7-diazaphenanthroline was dissolved. 50.6 g (0.32 mol) of potassium permanganate in 800 ml of water were added dropwise to the boiling solution with vigorous mechanical stirring, while stirring was carried out
175
40 from benzene using charcoal to provide. Output 2.4 g, so pl. 139.8 - 140 ° C., RЈ 0.16 ethyl acetate: methanol 90: 10, V NMR (200 MHz, CDC15) Ј: 3,397 at such a rate that the droplets per-, - 1Й / - „,
manganate immediately disintegrated. For 453 7p V B ° MHCHt L –sn; Gpiri
of this compound, the addition is accomplished in% IL) b, 475 {doublet 4H,
1 h. The reaction mixture was subjected to E: pyryl G 1 tletlet, 2H, 3- and 7-H 1,5-diazafluorene, each was refluxed for another 30 minutes, then the hot mixture was filtered. The filtrate was cooled to room temperature and extracted with chloroform. It was dried with sodium sulfate and chloroform was evaporated on a rotary evaporator. The crude product was recrystallized from water, then dried in a vacuum dryer over potassium hydroxide. The yield of pure 1,5-diazofluorin 9-one was 3.3 g, t „pl.

ten
15
5042516
158 - 159 ° С. The described reaction was repeated and another 3.3 g of material was obtained, which was combined with the first batch with,
Reduction of 1,5-diazafluoren-to 1,5-diazafluoren.
Following the procedure described in Example 11, 6.0 g (33 mmol) of 1,5-diazafluoren-9-one and 11.8 g (0.37 mol) of hydrazine were combined with 100 ml of diethylene glycol and quickly heated to 200 ° C. . The reaction was maintained at this temperature for 30 minutes, then for 3 hours at 180 ° C. Following the described treatment procedure, 4.69 g were obtained, m.p. 85 ° C. Recrystallization from cyclohexane yielded 4.0 g of pure 1,5-diazafluorene, m.p. 99 - 100 ° C.
Preparation of 9, (4-pyridinylmethyl) cyclopenta 1,2-b: 3.4 h Gdipiri dine.
Following the alkylation procedure described in Example 11, 2.0 g (12 mmol) of 1,5-dia, zafluorene, 4.68 g (29 mmol) of 4-picolyl chloride, 1.44 g (30 mmol) of a 50% solution sodium hydride was heated to 55 ° C in 10 ml
30 tetrahydrofuran and 25 ml of benzene until TLC (ethyl acetate: methanol 90:10) indicated the appearance of the product (R 0.065) and the disappearance of the starting diazafluorene (R 0.28)
35 The crude product was triturated with ether to give 2.90 g, mp. 133 137 ° C. It was treated by flash chromatography with ethyl acetate and recrystallized from benzene using charcoal for maintenance. Output 2.4 g, so pl. 139.8 - 140 ° C., RЈ 0.16 ethyl acetate: methanol 90: 10, V NMR (200 MHz, CDC15): 3.397 20
25
, -, 1st / - ",
453 7p V B ° MHCHt L –sn; Gpiri
E: pyriy l 1 typelet, 2H, 3- and 7-H 1,5-diazafluorene, each in meta relative to one of the nitrogen atoms); 7.802.7808 (doublet, 1H, 8-H diazafluorene); 70879-7.885 (doublet, 1H, 4-H diazofluorene); 8.097-8,122 (doublet, 4H, -pyridyls) .: 8,451-8,476 (doublet,
1H, 2-H diazafluorene); 8.741-8.763 (doublet, 1H, 6-H diazafluoren).
Mass spectrum: 350, 1531 (calculated); 350, 1529 (found); difference 0.0003 for С23Н1ИГ „
ten
/ 1750it25
Biochemical test procedure.
The effect of compounds on acetylcholine release (ACh) from rat cerebral cortical sections was tested using a section superfusion procedure with
Male Wister (Charles River) rats weighing 200 g were used. They were kept for at least seven days before the experiment in
a cage for animals with a 12- to 12-hour cycle day-night (the light was turned on at 6.00 h, turned off at 18.00 h). Rats were given excess feed and deionized water.
The rats were beheaded and the brain was immediately separated. A standard technique was used to prepare sections (0.3 mm thick) from the parietal cortex 20 of the brain and then cut into 0.25x0, 25 mm squares.
Sections (with a wet weight of approximately 100 mg) were incubated in 1C ml of Krebs-Ringer medium (KR) containing, mM: NaCl 116; KS1 3; CaCl g 1,3; Ma12 1,2; KH2P04 1.2; NaiSO 1.2; NANSO 25; glucose 11, to which 10jwCi H-choline was previously added with a specific activity of approximately 35 Ci / mmol, NEN and Ynmol of unlabeled choline, to obtain
final concentration M. Incubation was carried out for
25
thirty
18
the absorption of choline formed during the superfusion from phospholipids and the released ACh, which would be converted to unlabeled ACh and released instead of the previously labeled ACh. The medium was delivered using a 25-channel peristaltic pump and heated to 37 ° C in a thermostated stainless steel coil before the introduction of the superfusion column. Each column was supplied with a positional mobile valve that was allowed to quickly switch from KR low K medium to medium from high K, and two 10-channel position valves, which were used to switch from KR medium without a drug to KR medium containing a low and high K drug
After 15 minutes of washing from non-specific bound radioactivity, collection of minute fractions began. After three U-minute samples, KR medium was replaced with KR medium, in which the concentration of KC1 was increased to 25 mM (KR medium with high K) (S1}. Irritation, inducing depolarization, release with KR- environment with high K ended in the i-th minute. Medium that does not contain a drug, with low and
30 min at 37 ° C in an equilibrium flow of 35 K high, then replaced with medium 95% CCU Under these conditions, part of the absorbed radioactive choline was converted into radioactive ACh under the action of cholinergic nerve endings, stored in synaptic bubbles and released during depolarization with using high content environment
K +
After the label was inserted into the stored ACh, the sections were washed 3 times with non-radioactive KR medium and transferred to a superfusion device to measure the effect of the preparation on the ACh. The superfusion apparatus contained 10 thermostatic glass columns 5 mm in diameter, which were supplied with glass fiber filters.
40
45
50
Do with a drug or solvent containing low and high K KR medium and superfusion continued for three U-minute intervals, selected low-K KR medium, one U-minute high K medium selection (Sg.) and two-minute selection of medium KR with low K +
The drug was added to the medium using a 100-fold dilution of the appropriate concentrations of the drug (in 0% V% NaCl /% 0) KR medium with either low or high K +.
All superfusion fractions were collected in ampoules4 for a liquid scintillation counter. After superfusion, the medium was removed from the columns for cyF / F to maintain sections (approximately 10 mg of tissue / column). Su- 55 perfusion and extracted with 1.0 ml perfusion were carried out with a KR medium (0.5 0.1 N HCl solution. B superfusion ml / min) containing 10 K half-line-3 (HC-3 ). NS-3 prevents
These fractions and extracts were then added 12 ml of liquid to the counter.
18
0
five
0
five
0
the absorption of choline formed during the superfusion from phospholipids and the released ACh, which would be converted into unlabeled ACh and released instead of the previously labeled ACh. The medium was delivered using a 25-channel peristaltic pump and heated to 37 ° C in a thermostated stainless steel coil before the introduction of the superfusion column. Each column was supplied with a positional mobile valve that was allowed to quickly switch from KR low K medium to high K, and two 10-channel position valves, which were used to switch from KR-medium without drug to KR-medium containing drug, low and high K
After 15 minutes of washing from non-specific bound radioactivity, collection of minute fractions began. After three U-minute screenings, the KR medium was replaced with a KR medium, in which the concentration of KC1 was increased to 25 mM (KR medium with high K) (S1}. Irritation, inducing depolarization, release using KR-medium with high K ended in minute 1. Medium that does not contain the drug, with low and
5 high K, then replaced by
Do with a drug or solvent containing low and high K KR medium and superfusion continued for three U-minute intervals, selected low-K KR medium, one U-minute high K medium selection (Sg.) and two-minute selection of medium KR with low K +
The drug was added to the medium using a 100-fold dilution of the appropriate concentrations of the drug (in 0% V% NaCl /% 0) KR medium with either low or high K +.
All superfusion fractions were collected in ampoules4 for a liquid scintillation counter. After the superfusion, the medium was removed from the superfusion columns and extracted with 1.0 ml of a 0.1N HCl solution. In superfusion
perfusion and extracted in 1.0 ml of 0.1N HCl solution. In superfusion
These fractions and extracts were then added 12 ml of liquid to the counter.
scintillations, liciscinth (PEP), and samples were examined on a Packard Tricarb type liquid scintillation counter. No corrections for adding a cold product
The ratio, (when compared with control drugs that do not contain the drug for L), served as a measure of the ability of the drug to increase or decrease the stimulated stimulation release of acetylcholine. The data obtained in laboratory experiments on ACh-release are given in the table.
The increase,%, of the stimulation-induced release of acetylcholium in the rat cortex under laboratory conditions at a concentration, M
PG
ten
,-four
+13 +3 - -1-105 +17
:
- +222
+345
+71

+288
+264
+ 167
+ 125
+0
+57
+22
+222
+0
+87
+ 111
+338
+50
+14
+340
+221
+233
+465
+259
+375
+460
+ 42y
+ 6y
+359
+ 185
+227
+90
The test results show that the compounds obtained by the proposed method can be used in the treatment of mental deficiencies and / or deficiencies of neurological functions and / / psychological disorders in patients suffering from nervous system disorders such as Elzheymor, Parkinson's disease, senile dementia, dementia caused by repeated hemorrhages, Huntington disease, mental retardation
twig, myasthenia and t In contrast to the well-known anti-archsone drug 1-phenyl-1-cyclohexyl-3 (1-piperidino) propanol-1, which is not capable of increasing the release of acetylcholine, these compounds have the advantage

权利要求:
Claims (1)
[1]
Invention Formula
The method of obtaining / X-disubstituted aromatic and heteroaromatic compounds of General formula
X.,
i
X
CH2-Het2
20 gAe Net ,, and Het are 4-pyridyl or 3 pyridyl, and
X
F
Y
choose from: a) group
goX
where Q, when a is a double bond, is H, and X is C-phenyl, and when a is a double bond, Q is Hg or -CHOAc, and X 35 is, respectively, CH-phenyl or -C-phenyl;
B) groups
CH50
(c) groups
Oas
50
where A is CH2 or CH2CH: (d) groups
55 where A is O, S or a bond; R1 is H or CH3,
RZ is H, CH3, C2H, Br or OCH3; (e) groups
31
1 s
soy :)
Mi, Mb
where J ,, Jg, M, M5 independently of each other are N or CH, or their salts, characterized in that the compounds of the formula
vy / CHj
Where
. -h.
Have
has the indicated meanings provided that a is a double bond with a base in an aprotic solvent, the base being selected from sodium hydride, butyl lithium, lithium diisopropylamide or hexamethyldisilazide, the anionic product thus obtained is treated with a compound of the formula DCHjHe,
0
five
0
five
0
where D is halogen;
Hetj - has the indicated value, to obtain a monosubstituted compound, which is again treated with a base selected from the above group, the salt thus obtained is treated with a compound of the formula
DCHzHet2,
where D and Het2 have the indicated meanings,
and isolate the desired product as a base or as a salt or, if necessary, a compound, where a is a double bond, is reduced to a single bond or oxidized and acylated to the corresponding di-diacetate, followed by isolation of the desired product. base or salt.
Priority featured:
Ob.10.87 is a method for producing a compound according to claim 1, where J and Jg are N and M g- are CH or one of Mie and MЈ is N and the other is CH;
23.08.88 — A method for the preparation of all other compounds according to the claims,

类似技术:

公开号 | 公开日 | 专利标题

SU1750425A3|1992-07-23|Method of obtaining aromatic and heteroaromatic compounds

CA2787360C|2019-03-05|Pyrrol0[3,2-c]pyridinyl-4-benzamide compounds and their use as apoptosis signal-regulating kinase 1 inhibitors

DE69635560T2|2006-08-17|Camptothecin analogues, processes for their preparation, their use as medicaments and pharmaceutical compositions containing them

DE60309739T2|2007-10-31|Pyridine derivatives as modulators of the CB2 receptor

JP4051712B2|2008-02-27|Novel melatonin-acting β-carboline derivatives and analogs containing naphthalene structure, their production method and pharmaceutical use

US5874438A|1999-02-23|2,2'-bridged bis-2,4-diaminoquinazolines

TWI612962B|2018-02-01|Ethynyl derivatives

JP2010523725A|2010-07-15|Triazolopyridines as phosphodiesterase inhibitors for the treatment of skin diseases

DE3724164A1|1988-01-28|Novel 1,4-benzodiazepines, their preparation and use

CN113272014A|2021-08-17|Pyridazinone compound and use thereof

SK10399A3|2000-01-18|Pyridazino [4,5-b]-quinoline 5-oxide derivatives, their preparation and their use as glycine antagonists

CN105121440B|2017-05-24|Salt of pyrazoloquinoline derivative, and crystal thereof

CA2917602A1|2015-02-05|1,7-naphthyridine derivatives

JP2001519805A|2001-10-23|Compound

CN104640867A|2015-05-20|Novel compounds

TW201103905A|2011-02-01|5-alkynyl-pyridines

DD266355A5|1989-03-29|PROCESS FOR THE PREPARATION OF NEW 1,4-BENZODIOZEPINES

SU1169538A3|1985-07-23|Method of obtaining tricyclic compounds

CZ20003614A3|2001-01-17|Acylbenzoxazines for increasing synaptic response

DE19604919A1|1997-08-07|New 2,3-benzodiazepine derivatives, their production and use as medicines

DE60005349T2|2004-12-30|DITHIEPINO [6,5-B] PYRIDINE AND THESE COMPOSITIONS AND METHOD USED

EP0536173B1|1995-01-04|Pyridopyrazine derivatives for treating substance abuse and addiction

BG103685A|2000-06-30|Quinoxalindions

DE2418498A1|1974-11-07|FUSED PYRIMIDINS AND THEIR PRODUCTION

同族专利:

公开号 | 公开日

JP2563522B2|1996-12-11|

IE70440B1|1996-11-27|

IL87929A|1993-03-15|

NZ226460A|1991-06-25|

MY103920A|1993-10-30|

NO884433D0|1988-10-05|

FI93446C|1995-04-10|

EP0532054A1|1993-03-17|

KR890006230A|1989-06-12|

DE3887615T2|1994-05-11|

EP0311010B1|1994-02-02|

DK556888D0|1988-10-05|

DE3887615D1|1994-03-17|

CA1339127C|1997-07-29|

IE940118L|1989-04-06|

PT88669A|1988-11-01|

IE883025L|1989-04-06|

EP0532054B1|1999-06-09|

DE3856340T2|1999-11-18|

NO174390B|1994-01-17|

NO174390C|1994-04-27|

US5173489A|1992-12-22|

DE3856340D1|1999-07-15|

HUT48618A|1989-06-28|

DK556888A|1989-04-07|

KR970006101B1|1997-04-23|

AT181070T|1999-06-15|

FI884582A0|1988-10-05|

EP0311010A2|1989-04-12|

PT88669B|1992-12-31|

HU205900B|1992-07-28|

EP0311010A3|1991-01-30|

IL87929D0|1989-03-31|

AU628021B2|1992-09-10|

NO884433L|1989-04-07|

JPH01207268A|1989-08-21|

ES2061587T3|1994-12-16|

FI884582A|1989-04-07|

AU2350888A|1989-04-06|

FI93446B|1994-12-30|

引用文献:

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

CH372673A|1959-03-26|1963-10-31|Geigy Ag J R|Process for the preparation of new N-heterocyclic compounds|

GB897052A|1959-03-26|1962-05-23|Geigy Ag J R|Improvements in and relating to n-heterocyclic compounds|

US3232950A|1962-01-31|1966-02-01|Schering Corp|5-5-hydroxy-dibenzo[a,d]cyclohepta[1,4]diene and acid addition salts thereof|

CH443344A|1964-12-03|1967-09-15|Geigy Ag J R|Process for the preparation of new thiepin and oxepine derivatives|

GB1154976A|1967-02-21|1969-06-11|Pfizer Ltd|N-Phenyl Indoline Derivatives|

US3432523A|1967-05-02|1969-03-11|Mcneilab Inc|11,11a - dihydro - 2 - - 6 - hydroxy - 6h - benzocyclohept - indolin-1-ones|

US3397202A|1967-05-02|1968-08-13|Mcneilab Inc|11, 11alpha-dihydro-11alpha-hydroxy-2--11-r3-6eta-benzo [5, 6] cyclohept [1, 2, 3-cd] indolin-1, 6-diones and intermediates for their preparation|

US3525743A|1968-02-29|1970-08-25|American Home Prod|Phenothiazine derivatives|

US3502662A|1968-03-18|1970-03-24|American Home Prod|N--3-amino or iodo-propionamides and 4--thiosemicarbazones|

IL33324A|1968-11-29|1972-09-28|Bayer Ag|N-substituted imidazoles and their salts,their production,and pharmaceutical preparations containing them|

CH550189A|1971-01-08|1974-06-14|Ciba Geigy Ag|PROCESS FOR MANUFACTURING NEW DIBENZO THIEPINCARBONIC ACIDS.|

GB1456017A|1972-11-16|1976-11-17|Weir Electronics Ltd|Electrical power supplies|

GB1453828A|1972-12-08|1976-10-27|Kefalas As|Fluoro-substituted thiaxanthene derivatives|

JPS4985073A|1972-12-22|1974-08-15|

US3843635A|1973-02-26|1974-10-22|Janssen Pharmaceutica Nv|propyl)-triazaspirodecan-4-ones|

GB1464431A|1974-03-25|1977-02-16|Roche Products Ltd|Indolobenzazepine derivatives and a process for the manufacture thereof|

US3966762A|1974-06-03|1976-06-29|Sterling Drug Inc.|N-[6,7]-Dihydroindolo[1,7-ab][1]benzazepin-2-yl)methyl/phthalimide|

GB1451389A|1974-07-03|1976-09-29|Pierrel Spa|Indolobenzazepines|

DE2704934A1|1976-02-17|1977-08-18|Sandoz Ag|ORGANIC COMPOUNDS, THEIR PRODUCTION AND USE|

US4273860A|1977-12-28|1981-06-16|Eastman Kodak Company|Inhibition of image formation utilizing cobalt complexes|

CU21107A3|1978-02-10|1988-02-01|Hoffmann La Roche|DERIVATIVE PYRROLIDINES|

US4188485A|1978-06-16|1980-02-12|G. D. Searle & Co.|1-[methyl]-4-substituted piperidines and related compounds|

US4372960A|1980-12-12|1983-02-08|Warner-Lambert Company|Quaternary derivatives of N--2-oxo-1-pyrrolidine-acetamides as cognition activators|

EP0108715A1|1982-10-15|1984-05-16|Ciba-Geigy Ag|Dibenzazepine carboxamides|

US4452990A|1982-11-15|1984-06-05|Warner-Lambert Company|1-Aroyl-5-oxo-2-pyrrolidinepropanoic acids and related esters|

US4434169A|1983-01-03|1984-02-28|Warner-Lambert Company|Pharmaceutical compositions and methods|

CH656378A5|1983-05-02|1986-06-30|Sandoz Ag|Allylamine derivatives, process for their preparation, antimycotic agents containing them, and their use|

JPH047333B2|1983-12-27|1992-02-10|Tosoh Corp|

JPH0370708B2|1983-12-28|1991-11-08|Kyorin Seiyaku Kk|

DE3405332A1|1984-02-15|1985-08-22|Sandoz-Patent-GmbH, 7850 Lörrach|Novel allylamines, process for their preparation, and their use|

US4760083A|1986-04-10|1988-07-26|E. I. Dupont De Nemours & Company|3,3-disubstituted indolines|

US4806651A|1987-10-07|1989-02-21|E. I. Du Pont De Nemours And Company|Process for preparing 3,3-disubstituted indolines|

JP5998896B2|2012-12-10|2016-09-28|マツダ株式会社|Automatic transmission|US5300642A|1986-04-10|1994-04-05|The Du Pont Merck Pharmaceutical Company|α, α-disubstituted aromatics and heteroaromatics as cognition enhancers|

US4806651A|1987-10-07|1989-02-21|E. I. Du Pont De Nemours And Company|Process for preparing 3,3-disubstituted indolines|

US5087628A|1990-01-12|1992-02-11|Du Pont Merck Pharmaceutical Company|4,4'-[9H-fluoren-9-ylidenebis ]bispyrimidine for treating neurological disorders|

US5278045A|1990-02-28|1994-01-11|Du Pont Merck Pharmaceutical Company|Method and compositions to screen compounds for enhancement of the cholinergic, dopaminergic and serotonergic function|

US5171745A|1990-07-13|1992-12-15|Du Pont Merck Pharmaceutical Company|Method of treating neurological dysfunction using neutrotransmitter enhancers|

US5424430A|1992-01-16|1995-06-13|The Du Pont Merck Pharmaceutical Company|Disubstituted polycyclic systems and preparative methods therefor|

RU2051151C1|1992-01-16|1995-12-27|Дзе Дюпон Мерк Фармасьютикал Компани|Nitrogen-containing heterocyclic derivatives of fluorene|

WO1993014085A1|1992-01-16|1993-07-22|The Du Pont Merk Pharmaceutical Company|Novel neurotransmitter releasers useful for cognition enhancement|

US5698559A|1992-01-16|1997-12-16|The Dupont Merck Pharmaceutical Company|Disubstituted polycyclic systems as cognition enhancers|

US5272269A|1992-01-16|1993-12-21|The Du Pont Merck Pharmaceutical Company|Disubstituted polycyclic systems and preparative methods therefor|

EP0636132A1|1992-04-16|1995-02-01|The Du Pont Merck Pharmaceutical Company|Substituted nitrogen containing spiro compounds for use in treating cognitive deficits|

US5296478A|1992-10-07|1994-03-22|The Dupont Merck Pharmaceutical Co.|1-substituted oxindoles as cognition enhancers|

IL107251D0|1992-10-13|1994-01-25|Du Pont Merck Pharma|3,3-Disubstituted tri- and tetracyclic indolin-2-ones and pharmaceutical compositions comprising them|

US5594001A|1993-04-08|1997-01-14|The Dupont Merck Pharmaceutical Company|Polycyclic systems, and derivatives thereof, as neurotransmitter release enhancers useful in the treatment of cognitive disorders|

RU2152944C1|1993-04-08|2000-07-20|Дзе Дюпон Мерк Фармасьютикал Компани|Polycyclic compounds, their derivatives, pharmaceutical preparations as enhancers and method of treatment of intellectual activity disorder|

AU4293193A|1993-04-28|1994-11-21|Du Pont Merck Pharmaceutical Company, The|Novel trisubstituted aromatic amines useful for the treatment of cognitive deficits|

US5308851A|1993-06-03|1994-05-03|The Du Pont Merck Pharmaceutical Company|Bispyridyl-containing heterocycles useful for treating cognitive disorders|

US5854232A|1994-04-29|1998-12-29|Pfizer Inc.|Acyclic anc cyclic amides as neurotransmitter release enhancers|

GB9412573D0|1994-06-22|1994-08-10|Celltech Ltd|Chemical compounds|

US5750528A|1995-02-01|1998-05-12|The Dupont Merck Pharmaceutical Company|Blockade of neuronal m-channels as a therapeutic approach to the treatment of neurological disease|

HU9902133A3|1996-01-16|2000-04-28|Bristol Myers Squibb Co|Aromatic inhibitors of microsomal triglyceride transfer protein|

KR100579599B1|1996-08-29|2006-08-21|삼성전자주식회사|How to Display Television Images on Portable and Portable Computers with Built-in TV Tuner|

US5760246A|1996-12-17|1998-06-02|Biller; Scott A.|Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method|

US6262081B1|1998-07-10|2001-07-17|Dupont Pharmaceuticals Company|Composition for and method of treating neurological disorders|

US20040175691A1|1998-12-03|2004-09-09|Brown Barry S.|Use of the KCNQ2 and KCNQ3 genes for the discovery of agents useful in the treatment of neurological disorders|

DE10101020A1|2001-01-11|2002-07-18|Clariant Internat Ltd Muttenz|Fluorinated fluorenes and their use in liquid-crystal mixtures|

ES2524922T3|2005-05-10|2014-12-15|Intermune, Inc.|Pyridone derivatives to modulate the stress-activated protein kinase system|

CN102099036B|2008-06-03|2015-05-27|英特芒尼公司|Compounds and methods for treating inflammatory and fibrotic disorders|

CN102382109A|2010-08-30|2012-03-21|苏州市贝克生物科技有限公司|Preparation method of 1,8-dinitro-9-fluorenone|

AR092742A1|2012-10-02|2015-04-29|Intermune Inc|ANTIFIBROTIC PYRIDINONES|

RU2692485C2|2014-04-02|2019-06-25|Интермьюн, Инк.|Antifibrous pyridinones|

法律状态:

优先权:

申请号 | 申请日 | 专利标题

US10515687A| true| 1987-10-06|1987-10-06|

US07/234,382|US5173489A|1986-04-10|1988-08-23|α,α-disubstituted aromatics and heteroaromatics as cognition enhancers|

[返回顶部]